BCTXZ vs BDRX

BriaCell Therapeutics Corp. War vs Biodexa Pharmaceuticals plc — Valuation Comparison 2026

BCTXZ

Pharmaceutical Preparations
BriaCell Therapeutics Corp. War
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$0.08
Last close
Models
1/13
Active
VS

BDRX

Pharmaceutical Preparations
Biodexa Pharmaceuticals plc
Quality
1.7
out of 10
Value Trap
Price
$3.47
Last close
Models
5/13
Active

Model-by-Model Comparison

ModelType BCTXZ Fair ValueBCTXZ Upside BDRX Fair ValueBDRX Upside
Bayesian DCF Intrinsic $0.85 -75.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.31 +227.6%
Dynamic NAV Asset-Based $16.83 +384.9%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BCTXZ vs BDRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BCTXZ vs BDRX — Which Stock Is More Undervalued?

BCTXZ scores higher with a 4.4/10 quality rating vs BDRX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BriaCell Therapeutics Corp. War (BCTXZ) and Biodexa Pharmaceuticals plc (BDRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BCTXZ currently trades at $0.08 with a QOC of 4.4/10, while BDRX trades at $3.47 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).